Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool April 12, 2011 Brian Orelli	How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool July 23, 2008 Brian Lawler	No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results.
The Motley Fool October 27, 2010 Brian Orelli	Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan.
The Motley Fool October 27, 2011 Brian Orelli	DEFINE First, CONFIRM Second, See Shares Rise 60% Third Biogen CONFIRMs it has a new blockbuster drug and shares jump.
The Motley Fool June 23, 2011 Brian Orelli	One Less Oral MS Drug to Worry About But competition is still tough.
The Motley Fool May 2, 2007 Brian Lawler	Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note.
The Motley Fool November 1, 2006 Brian Lawler	Biogen Idec's Booming Results Even with guidance for 2006 non-GAAP earnings per share raised to more than $2.20, Biogen shares are trading at a reasonable 24 times earnings, considering the level of scale and sales growth it has exhibited this year.
The Motley Fool October 22, 2008 Brian Orelli	Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places.
The Motley Fool April 17, 2009 Brian Orelli	When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future?
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool January 21, 2011 Brian Orelli	Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down.
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.
The Motley Fool February 2, 2011 Brian Orelli	A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker.
The Motley Fool April 22, 2011 MedCity News	Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments.
The Motley Fool September 30, 2009 Brian Orelli	Less Is More for Novartis That makes it simple enough.
The Motley Fool February 7, 2008 Brian Lawler	Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition.
The Motley Fool October 30, 2008 Brian Orelli	Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool January 9, 2008 Brian Lawler	Checking In on Biogen Biogen Idec presents at the JPMorgan Healthcare Conference, reiterating its long-term guidance of 15% compound annual sales growth and 20% average non-GAAP earnings-per-share growth from 2007 through 2010.
The Motley Fool January 25, 2010 Brian Orelli	Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool May 26, 2010 Brian Orelli	Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool October 26, 2009 Brian Orelli	For Tysabri, 23 Is 10 Too Many The side effect rate is important.
The Motley Fool June 3, 2010 Brian Orelli	When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors.
The Motley Fool April 25, 2008 Brian Lawler	Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool August 1, 2011 Brian Orelli	Bravo? Not Really. Teva's oral multiple sclerosis drug, laquinimod, fails to impress.
The Motley Fool October 20, 2009 Brian Orelli	All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug.
The Motley Fool December 9, 2010 Brian Orelli	Here Comes Another Oral MS Drug Good for Teva, bad for the rest.
The Motley Fool February 6, 2009 Brian Orelli	Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board.
The Motley Fool January 12, 2010 Brian Orelli	Tysabri: It's a Blockbuster! Yawn. So What? Is it really a big deal that Tysabri finally achieved blockbuster status?
The Motley Fool August 26, 2008 Brian Lawler	FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs.
The Motley Fool December 15, 2008 Brian Orelli	A Potentially Game-Changing MS Drug The newest data looks good, but longer studies will be the key for Novartis.
The Motley Fool July 17, 2009 Brian Orelli	Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva.
The Motley Fool September 23, 2010 Brian Orelli	A Blockbuster in Due Time Novartis' new multiple sclerosis drug, Gilenya, isn't king yet.
The Motley Fool July 26, 2006 Brian Lawler	Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
The Motley Fool June 30, 2009 Brian Orelli	Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits.
The Motley Fool February 22, 2011 Brian Orelli	Biogen and Elan's Growing Problem More cases of potentially lethal PML.
The Motley Fool March 11, 2005 Karl Thiel	Better Times at Biogen IDEC Is now the time to buy this pharmaceutical?
The Motley Fool February 8, 2005 Charly Travers	Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance.
The Motley Fool March 26, 2009 Brian Orelli	R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales.
The Motley Fool August 10, 2011 Brian Orelli	A Jab a Month Is All We Ask Biogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects.
The Motley Fool September 4, 2009 Brian Orelli	The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up.